Dissemination (Meeting Coverage)

JAK2V617F variant allele frequency (VAF) >50% is associated with an increased risk of venous thrombosis in patients with polycythaemia vera (PV). This independent predictor distinguished between patients who were classified...

Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukemia (ALL). Differences in leukemia biology or disease prognosticators do...

The combination therapy of eprenetapopt plus azacytidine showed favorable efficacy and safety in patients with TP53-mutant myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukemia (AML). Patients with biallelic...

Liposomal daunorubicin/cytarabine (CPX-351) therapy did not result in different overall survival (OS) outcomes or response rates than venetoclax plus HMA therapy in patients with acute myeloid leukemia (AML) between 60 and 75...

The combination regimen of low-dose tacrolimus plus high-dose dexamethasone provides benefits over high-dose dexamethasone monotherapy in patients with immune thrombocytopenia (ITP). Both the initial response rates and the...

Talquetamab plus daratumumab demonstrated durable and deep responses in heavily pre-treated patients with refractory multiple myeloma (MM). Furthermore, the combination regimen was tolerable and did not show overlapping...

Scientific Sessions Programming For Presenters and Moderators Specialty Focused Programming Late-Breaking Science Online Program Planner CME/CE Credit Mobile Meeting Guide Live Sessions Session CH.AOS.463 226 – Impact of...

Source: American Heart Association Scientific Sessions 2021 “One World. Together for Science.” #AHA21 Join the American Heart Association Scientific Sessions 2021 virtual platform for the global cardiovascular event...

To Come…

To Come…

To Come….

This year’s Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, the leading research and educational conference for MS healthcare professionals in North America, kicks off tomorrow, October 25 through October...

 Findings presented at ECTRIMS 2021 suggest that deep, persistent B-cell depletion is linked to reduced disease activity Results from a new analysis of the inebilizumab pivotal Phase 2/3 N-MOmentum trial were presented this year...

Only a third of Medicare beneficiaries were persistent with anti-VEGF monotherapy each year. Overall, two-thirds of patients treated with anti-VEGF at baseline (BL) reported similar or better visual function after 2 years....

There are geographic disparities in access to clinical trial sites for neovascular age-related macular degeneration (nAMD) in the US. While proximity to urban centers is beneficial for efficiency and retention of subjects, the...

Analysis suggests that daily self-imaging generated images of satisfactory quality for human grading and automated analysis of fluid volume over time permitting a novel paradigm of monitoring. Home OCT may allow personalized...

The average patient with neovascular age-related macular degeneration (nvAMD) would not qualify for the trials that determine current standards of care. Clinical trial methodology could be to blame for real-world patients having...

Data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS) will be highlighted at the upcoming 37th Congress of the European Committee for Treatment and...

A total of 10 Janssen-sponsored data abstracts on MS research will be presented at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) virtual congress from October 13 to 15, in Vienna,...